Literature DB >> 8737685

Open chest and delayed sternal closure after cardiac surgery.

J T Christenson1, J Maurice, F Simonet, V Velebit, M Schmuziger.   

Abstract

OBJECTIVES: Open chest (OC) and subsequent delayed sternal closure (DSC) has been described as a useful method in the treatment of the severely impaired heart after cardiac surgery.
METHODS: Prolonged open chest was used in 142 to 3373 adult cardiac operations (4.2%) between January 1987 and December 1993. The indications were: hemodynamic compromise (121), intractable bleeding (9) and arrhythmias (12). Delayed sternal closure was carried out in 123 of 142 patients at a mean of 2.0 +/- 1.4 days (range 0.5-8 days). Open chest and DSC were used proportionally more frequently after combined cardiac surgery (28/293, 9.6%) than after coronary artery bypass grafting (CABG) alone (108/2891, 3.7%) or valve operation (6/230, 2.6%).
RESULTS: Ninety-seven of the 123 who had DSC (78.9%) survived and were discharged an average of 8.6 +/- 4.2 days after closure. Fourty-five patients died: 19 before DSC and 26 after this method. Mortality was related to indications for OC: when the indication was low cardiac output the mortality was 38.6%, for hemodynamic collapse on closure 0%, diffuse bleeding 33.3% and arrhythmias 27.3%. Delayed sternal closure in patients without intraaortic balloon pump support was more likely to be successful (mortality rate 4/25, 16.0% versus 35/76, 46.3%, P < 0.01). Superficial sternal wound infection occurred in 2 of 123 (1.6%) patients after DSC, mediastinitis in 1 (0.8%) and sternal dehiscence in 3 (2.4%) patients, which does not differ from a control population that had primary sternal closure. The follow-up of 97 survivors at an average of 28 +/- 4 months revealed an improvement of NYHA class by 1.4 +/- 0.4. There were 16 deaths (13 cardia-related) during the follow-up period and 3 redo CABG. One case of sternal osteomyelitis occurred without any other late sternal morbidity.
CONCLUSIONS: This study shows that OC with DSC is a beneficial adjunct in the treatment of postoperatively impaired cardiac function, profuse hemorrhage and persistent arrhythmias. It can be performed without increased sternal morbidity. Long-term results are also encouraging.

Entities:  

Mesh:

Year:  1996        PMID: 8737685     DOI: 10.1016/s1010-7940(96)80087-x

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  A case report of thoracic compartment syndrome in the setting of penetrating chest trauma and review of the literature.

Authors:  Michael W Wandling; Gary C An
Journal:  World J Emerg Surg       Date:  2010-07-30       Impact factor: 5.469

2.  Open-chest management after heart transplantation.

Authors:  Hiroo Takayama; Richard J Leone; Gabriel S Aldea; Daniel P Fishbein; Edward D Verrier; Christopher T Salerno
Journal:  Tex Heart Inst J       Date:  2006

Review 3.  Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.

Authors:  Sebastian Harder; Ute Klinkhardt; John M Alvarez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Donor-Recipient Weight Match in Pediatric Heart Transplantation: Liberalizing Weight Matching with Caution.

Authors:  Ming Chen; Li Xu; Wenjing Yu; Xingyu Qian; Zhenqi Rao; Jingrong Tu; Nianguo Dong; Fei Li
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-07

Review 5.  Timing of surgical intervention for compartment syndrome in different body region: systematic review of the literature.

Authors:  Federico Coccolini; Mario Improta; Edoardo Picetti; Luigi Branca Vergano; Fausto Catena; Nicola de 'Angelis; Andrea Bertolucci; Andrew W Kirkpatrick; Massimo Sartelli; Paola Fugazzola; Dario Tartaglia; Massimo Chiarugi
Journal:  World J Emerg Surg       Date:  2020-10-21       Impact factor: 5.469

6.  Commentary: Delayed sternal closure-an open and not-so-shut case.

Authors:  Rachel Eikelboom; Michael H Yamashita
Journal:  JTCVS Tech       Date:  2020-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.